The Children's Hospital, Denver, has participated in the WP Cancer Group as a full member since 1980. Since that time, we have participated in the majority of group wide trials and have consistently been in the top half of institutions in numbers of patients entered on CCG protocols. Several members of our staff have important leadership positions within CCG: Dr. Gerald Haase was named Group Vice Chairman in 1991 and he is also Chairman of the Surgery Discipline Committee. Dr. Odom is a member of the AMC Steering Committee and the AML Strategy Group. Our clinical Research Associate was recently appointed to the newly formed CCG Data Management Committee. Our institution was chosen as one of five across the country to participate in cooperative pilot studies for the treatment of intermediate and poor prognosis newly diagnosed acute lymphoblastic leukemia. Additionally, our nurses have been very active in CCG protocol committees. Our Cytogeneticist and two cardiologists actively participate in the Cytogenetics and Cardiology Committees. The Children;s Hospital, Denver, has brought to the group concepts in the area of induction therapy for acute myeloid leukemia and treatment of high grade astrocytoma. We have been conducting a single institution pilot study incorporating intraarterial Cis Platinum and continuous infusion Adriamycin for the treatment of newly diagnosed osteosarcoma since 1988 (initiated in hiatus period between open front line CCG protocols for treatment of this resectable solid tumors in children. We have experience with nearly 50 patients so treated. This data has been evaluated by the CCG Radiation Therapy and Surgery Committees and is in manuscript preparation. This modality will soon be open for group wide participation. Patients have in the past and will continue to be referred to this institution for this form of treatment. Our Data Management section consistently ranks as one of the best in CCG and we have therefore served as advisors and consultants to other CCG institutions and potential members. Additionally, we are supporting, through profit monies, along with a few other CCG institutions, a computer expert who has designed a software program for management of CCG protocol data, to install this system in our institution to serve as a pilot for CCG of this mechanism of information handling. We have several young investigators with a broad range of interests who are eager to join CCG protocol committees. Our institution has been audited four times, once with an NCI observer for compliance with research requirements and found to have no deviations from Federal regulations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA028851-18
Application #
2607995
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Program Officer
Smith, Malcolm M
Project Start
1994-04-05
Project End
1998-11-30
Budget Start
1997-12-11
Budget End
1998-11-30
Support Year
18
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Children's Hospital of Denver
Department
Type
DUNS #
076443316
City
Aurora
State
CO
Country
United States
Zip Code
80045
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Cooper, R; Khakoo, Y; Matthay, K K et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 36:623-9
Sposto, R; Meadows, A T; Chilcote, R R et al. (2001) Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Med Pediatr Oncol 37:432-41
Heifetz, S A; Cushing, B; Giller, R et al. (1998) Immature teratomas in children: pathologic considerations: a report from the combined Pediatric Oncology Group/Children's Cancer Group. Am J Surg Pathol 22:1115-24